Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert Patrick Giugliano, M.D.

Co-Author

This page shows the publications co-authored by Robert Giugliano and Marc Sabatine.
Connection Strength

14.071
  1. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. JAMA Cardiol. 2018 09 01; 3(9):823-828.
    View in: PubMed
    Score: 0.777
  2. Clinical benefits of evolocumab appear less than hoped - Authors' reply. Lancet. 2018 03 10; 391(10124):934-935.
    View in: PubMed
    Score: 0.751
  3. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. JAMA Cardiol. 2017 12 01; 2(12):1385-1391.
    View in: PubMed
    Score: 0.737
  4. Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target. JAMA Cardiol. 2017 09 01; 2(9):935-936.
    View in: PubMed
    Score: 0.725
  5. Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field? J Am Coll Cardiol. 2015 Jun 23; 65(24):2638-2651.
    View in: PubMed
    Score: 0.622
  6. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. JAMA Cardiol. 2022 Mar 01; 7(3):250-256.
    View in: PubMed
    Score: 0.247
  7. Assessment of the Change of a Continuous Variable as a Function of its Initial Value-Reply. JAMA Cardiol. 2021 11 01; 6(11):1342-1343.
    View in: PubMed
    Score: 0.242
  8. Myocardial Infarction and Evolocumab-Reply. JAMA Cardiol. 2021 10 01; 6(10):1222-1223.
    View in: PubMed
    Score: 0.240
  9. Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL. Circulation. 2021 11 23; 144(21):1732-1734.
    View in: PubMed
    Score: 0.239
  10. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial. JAMA Cardiol. 2021 02 01; 6(2):139-147.
    View in: PubMed
    Score: 0.230
  11. Letter to the editor re: 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'. Expert Rev Clin Pharmacol. 2021 02; 14(2):281-282.
    View in: PubMed
    Score: 0.229
  12. Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition. JAMA Cardiol. 2020 Nov 13.
    View in: PubMed
    Score: 0.226
  13. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020 11 21; 396(10263):1637-1643.
    View in: PubMed
    Score: 0.226
  14. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial. JAMA Cardiol. 2020 08 01; 5(8):952-957.
    View in: PubMed
    Score: 0.222
  15. Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial. JAMA Cardiol. 2020 07 01; 5(7):787-793.
    View in: PubMed
    Score: 0.220
  16. An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. JAMA Cardiol. 2020 06 01; 5(6):709-713.
    View in: PubMed
    Score: 0.219
  17. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke. 2020 05; 51(5):1546-1554.
    View in: PubMed
    Score: 0.217
  18. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation. 2020 05 19; 141(20):1600-1607.
    View in: PubMed
    Score: 0.217
  19. Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. J Am Coll Cardiol. 2020 01 28; 75(3):289-300.
    View in: PubMed
    Score: 0.214
  20. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation. 2019 10 15; 140(16):1308-1317.
    View in: PubMed
    Score: 0.209
  21. Correctly understanding the diabetes data in FOURIER. Diabetes Obes Metab. 2019 10; 21(10):2342-2343.
    View in: PubMed
    Score: 0.206
  22. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. JAMA Cardiol. 2019 07 01; 4(7):613-619.
    View in: PubMed
    Score: 0.206
  23. Interindividual and Intraindividual Responses to PCSK9 Inhibition-Reply. JAMA Cardiol. 2019 06 01; 4(6):600-601.
    View in: PubMed
    Score: 0.204
  24. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019 03 19; 139(12):1483-1492.
    View in: PubMed
    Score: 0.202
  25. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data. JAMA Cardiol. 2019 01 01; 4(1):59-63.
    View in: PubMed
    Score: 0.199
  26. Modes and timing of death in 66?252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 11 07; 39(42):3810-3820.
    View in: PubMed
    Score: 0.197
  27. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER. Circulation. 2018 08 21; 138(8):756-766.
    View in: PubMed
    Score: 0.194
  28. Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial. JAMA Cardiol. 2018 08 01; 3(8):749-753.
    View in: PubMed
    Score: 0.193
  29. Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation. 2018 07 10; 138(2):131-140.
    View in: PubMed
    Score: 0.188
  30. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017 11 16; 377(20):1997.
    View in: PubMed
    Score: 0.184
  31. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017 Nov 16; 377(20):1997.
    View in: PubMed
    Score: 0.184
  32. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018 01 23; 137(4):338-350.
    View in: PubMed
    Score: 0.184
  33. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017 10 01; 2(10):1069-1078.
    View in: PubMed
    Score: 0.182
  34. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017 12; 5(12):941-950.
    View in: PubMed
    Score: 0.182
  35. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017 Oct 28; 390(10106):1962-1971.
    View in: PubMed
    Score: 0.181
  36. Evolocumab in Patients with Cardiovascular Disease. N Engl J Med. 2017 08 24; 377(8):787-8.
    View in: PubMed
    Score: 0.181
  37. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017 08 17; 377(7):633-643.
    View in: PubMed
    Score: 0.181
  38. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab. JAMA Cardiol. 2017 05 01; 2(5):556-560.
    View in: PubMed
    Score: 0.177
  39. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 05 04; 376(18):1713-1722.
    View in: PubMed
    Score: 0.175
  40. Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. Clin Cardiol. 2017 Feb; 40(2):59-65.
    View in: PubMed
    Score: 0.175
  41. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J Med. 2016 12 01; 375(22):2144-2153.
    View in: PubMed
    Score: 0.172
  42. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016 Sep 27; 316(12):1289-97.
    View in: PubMed
    Score: 0.170
  43. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Am Heart J. 2016 Mar; 173:94-101.
    View in: PubMed
    Score: 0.161
  44. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1500-9.
    View in: PubMed
    Score: 0.153
  45. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Jun 06; 385(9984):2280-7.
    View in: PubMed
    Score: 0.153
  46. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). J Am Coll Cardiol. 2014 Feb 11; 63(5):430-3.
    View in: PubMed
    Score: 0.139
  47. Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. J Cardiovasc Pharmacol Ther. 2013 Nov; 18(6):555-9.
    View in: PubMed
    Score: 0.138
  48. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation. 2013 Aug 27; 128(9):962-9.
    View in: PubMed
    Score: 0.136
  49. Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. Clin Cardiol. 2013 Apr; 36(4):222-7.
    View in: PubMed
    Score: 0.133
  50. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012 Dec 08; 380(9858):2007-17.
    View in: PubMed
    Score: 0.130
  51. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2012; 35(7):385-91.
    View in: PubMed
    Score: 0.126
  52. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005 Apr 26; 111(16):2042-9.
    View in: PubMed
    Score: 0.077
  53. Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction. Am J Cardiol. 2005 Jan 15; 95(2):228-33.
    View in: PubMed
    Score: 0.076
  54. Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Am J Cardiol. 2004 Jun 01; 93(11):1362-7, A5-6.
    View in: PubMed
    Score: 0.072
  55. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Circulation. 2004 Feb 24; 109(7):874-80.
    View in: PubMed
    Score: 0.071
  56. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. Am Heart J. 2002 Jun; 143(6):966-70.
    View in: PubMed
    Score: 0.063
  57. Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2022 Mar; 15(3):e011382.
    View in: PubMed
    Score: 0.062
  58. Reply: Analyzing IMPROVE-IT Beyond LDL Cholesterol. J Am Coll Cardiol. 2022 02 01; 79(4):e153.
    View in: PubMed
    Score: 0.062
  59. Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. Eur Heart J. 2021 12 14; 42(47):4821-4829.
    View in: PubMed
    Score: 0.061
  60. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. J Am Coll Cardiol. 2021 10 12; 78(15):1499-1507.
    View in: PubMed
    Score: 0.060
  61. Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. Circulation. 2021 07 20; 144(3):249-251.
    View in: PubMed
    Score: 0.059
  62. Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects - A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. Circ J. 2021 10 25; 85(11):2063-2070.
    View in: PubMed
    Score: 0.059
  63. Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 02 16; 143(7):685-695.
    View in: PubMed
    Score: 0.058
  64. Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circ Genom Precis Med. 2021 02; 14(1):e003006.
    View in: PubMed
    Score: 0.057
  65. Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. J Am Coll Cardiol. 2021 01 26; 77(3):259-267.
    View in: PubMed
    Score: 0.057
  66. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation. 2021 02 02; 143(5):470-478.
    View in: PubMed
    Score: 0.057
  67. Cognition After Lowering LDL-Cholesterol With Evolocumab. J Am Coll Cardiol. 2020 05 12; 75(18):2283-2293.
    View in: PubMed
    Score: 0.055
  68. Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2019 12 17; 74(24):3013-3022.
    View in: PubMed
    Score: 0.053
  69. Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial. Circulation. 2020 02 25; 141(8):616-623.
    View in: PubMed
    Score: 0.053
  70. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. J Am Coll Cardiol. 2019 10 29; 74(17):2132-2146.
    View in: PubMed
    Score: 0.053
  71. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. J Am Coll Cardiol. 2019 06 18; 73(23):2961-2970.
    View in: PubMed
    Score: 0.051
  72. Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications. J Cardiovasc Pharmacol Ther. 2018 09; 23(5):423-432.
    View in: PubMed
    Score: 0.048
  73. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol. 2017 06 01; 2(6):598-607.
    View in: PubMed
    Score: 0.045
  74. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res. 2016 06; 57(6):1086-96.
    View in: PubMed
    Score: 0.041
  75. Prognostic implications of low level cardiac troponin elevation using high-sensitivity cardiac troponin T. Clin Cardiol. 2015 Apr; 38(4):230-5.
    View in: PubMed
    Score: 0.038
  76. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014 Sep 01; 35(33):2249-59.
    View in: PubMed
    Score: 0.036
  77. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014 Apr 08; 63(13):1278-1288.
    View in: PubMed
    Score: 0.035
  78. Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. Clin Cardiol. 2014 Mar; 37(3):160-6.
    View in: PubMed
    Score: 0.035
  79. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014 Jan 14; 129(2):234-43.
    View in: PubMed
    Score: 0.035
  80. Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome. Clin Chem. 2014 Jan; 60(1):158-64.
    View in: PubMed
    Score: 0.034
  81. Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction. Chronobiol Int. 2012 Dec; 29(10):1390-6.
    View in: PubMed
    Score: 0.032
  82. Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. Am Heart J. 2010 Jan; 159(1):55-62.
    View in: PubMed
    Score: 0.027
  83. A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. Eur Heart J. 2007 Sep; 28(17):2070-6.
    View in: PubMed
    Score: 0.022
  84. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol. 2006 Jul 04; 48(1):37-42.
    View in: PubMed
    Score: 0.021
  85. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation. 2004 Feb 10; 109(5):580-6.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.